Ibipinabant

Ibipinabant (SLV319, BMS-646,256) was designed by Jos Lange at Solvay Pharmaceuticals in 2000. Nowadays, it is an in vivo active pharmacological tool used in scientific research which acts as a potent and highly selective CB₁ antagonist.^[1] It has potent anorectic effects in animals,^[2] and was researched for the treatment of obesity, although CB₁ antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB₁ antagonists.^[3][4][5] SLV330, which is a structural analogue of Ibipinabant, was reported active in animal models related to the regulation of memory, cognition, as well as in addictive behavior.^[6][7] An atom-efficient synthesis of ibipinabant has been reported.^[8]

Ibipinabant

Clinical data
ATC code	none
Identifiers
IUPAC name 4S-(−)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine
CAS Number	464213-10-3 Y
PubChem CID	9826744
ChemSpider	24765166 N
UNII	O5CSC6WH1T
KEGG	D09349 Y
ChEMBL	ChEMBL158784 N
CompTox Dashboard (EPA)	DTXSID70963572
ECHA InfoCard	100.158.931
Chemical and physical data
Formula	C24H22Cl2N4O2S
Molar mass	501.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES c2cc(Cl)ccc2C1=NN(C(NC)=NCS(=O)(=O)c3ccc(Cl)cc3)CC1c4ccccc4
InChI InChI=1S/C24H22Cl2N4O2S/c1-27-24(28-16-33(31,32)21-13-11-20(26)12-14-21)30-15-22(17-5-3-2-4-6-17)23(29-30)18-7-9-19(25)10-8-18/h2-14,22H,15-16H2,1H3,(H,27,28)/t22-/m1/s1 N Key:BSFKAVCGRDMWTK-JOCHJYFZSA-N N
NY (what is this?)  (verify)

See also

• Cannabinoid receptor antagonist